Physician profile
Lena Gowring
NPI 1639343312
$5,177.09
in general payments reported to CMS, 2019-2025
24 companies · $611 in 2025
The $611 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $288 · 2021: $718 · 2022: $1,080 · 2023: $509 · 2024: $1,046 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.92 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,502.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $588.26 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $526.08 | 2019 | |
| Janssen Biotech, INC. | $307.00 | 2021-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $280.01 | 2019-2025 | |
| Lilly USA, LLC | $252.80 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $241.03 | 2019-2024 | Bimzelx, Cimzia |
| Leo Pharma INC. | $211.52 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $188.04 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $186.64 | 2021-2024 | Libtayo, Dupixent |
| Genzyme Corporation | $168.75 | 2021-2022 | |
| Revance Therapeutics, INC. | $125.00 | 2024 | Daxxify |
| Incyte Corporation | $86.63 | 2022-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $78.77 | 2023-2025 | Sotyktu |
| Pfizer INC. | $75.10 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $72.56 | 2021-2023 | Puraply |
| Genentech USA, INC. | $56.37 | 2019-2024 | Erivedge |
| Arcutis Biotherapeutics, INC. | $54.00 | 2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.87 | 2023 | Spevigo, Cyltezo |
| Allergan, INC. | $41.89 | 2022 | |
| Amgen INC. | $26.84 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $24.34 | 2021 | |
| Dermavant Sciences, INC. | $19.41 | 2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $15.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lena Gowring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.